rectitioner's Docket No. MPI98-105P1RCP2DV1M
--

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

h re application of:

Raju, Jeyaseelan

Application No.:

10/626,173

Group No.:

1652

Filed:

July 24, 2003

Examiner:

Monshipouri, Maryam

For:

NOVEL CARK PROTEIN AND NUCLEIC ACID MOLECULES AND USES

THEREFOR

Mail Stop Amendment **Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed:

() Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

OR

M After three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but before the mailing date of either:

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for X Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

× with sufficient postage as first class mail. as "Express Mail Post Office to Addressee" Mailing Label No.

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: January 11, 2005

Sean Hunziker

(type or print name of person certifying)

*WARNING:Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI98-105P1RCP2DV1M

- (1) a final action under Section 1.113,
- (2) a notice of allowance under Section 1.311, or
- (3) an action that otherwise closes prosecution in the application

whichever occurs first.

 Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00). Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1). No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2). OR The information disclosure statement transmitted herewith is being filed after a final action under Section 1.113, or a notice of allowance under Section 1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee. In accordance with the requirements of 37 C.F.R. Section 1.97(d): A. [] Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00). B. [] Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1). C. [] No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designa	
communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1). [] No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2). OR [] The information disclosure statement transmitted herewith is being filed after a final action under Section 1.113, or a notice of allowance under Section 1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee. [] In accordance with the requirements of 37 C.F.R. Section 1.97(d): A. [] Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00). B. [] Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the	
communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2). OR (1) The information disclosure statement transmitted herewith is being filed after a final action under Section 1.113, or a notice of allowance under Section 1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee. (2) In accordance with the requirements of 37 C.F.R. Section 1.97(d): A. (3) Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00). B. (4) Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the	communication from a foreign patent office in a counterpart foreign application not more than three
 The information disclosure statement transmitted herewith is being filed after a final action under Section 1.113, or a notice of allowance under Section 1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee. In accordance with the requirements of 37 C.F.R. Section 1.97(d): Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00). Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1). No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the 	communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information
 Section 1.113, or a notice of allowance under Section 1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee. [] In accordance with the requirements of 37 C.F.R. Section 1.97(d): A. [] Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00). B. [] Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1). C. [] No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the 	OR
 A. [] Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00). B. [] Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1). C. [] No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the 	Section 1.113, or a notice of allowance under Section 1.311, whichever occurs first, but before, or
submission of an information disclosure statement under Section 1.97(c). (\$180.00). B. [] Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1). C. [] No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the	[] In accordance with the requirements of 37 C.F.R. Section 1.97(d):
in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1). C. [] No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the	
in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the	in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section
	in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the

Practitioner's Docket No. MPI98-105P1RCP2DV1M

FEE PAYMENT

3. (x) The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).

() A ₁	oplicant believes no fee is due in connection with	this submission	<u> </u>		
					Fee due	\$180.00
		METHOD OF PAYME	NT OF FEE			
4.	()	Attached is a check in the amount of \$	·			
-	(X)	Charge Account No. 501668 in the amount of	\$180.00			
	[X]	A duplicate of this request is attached.				

If any additional fees are due, please charge Account 501668.

January 11, 2005	MILLENNIUM PHARMACEUTICALS, INC.
	By Jawa Clarte
	Mario Cloutier
	Limited Recognition Under 37 C.F.R. §10.9(b)
	40 Lansdowne Street
	Cambridge, MA 02139
	Telephone – (617) 577-3522
	Facsimile – (617) 551-8820

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re appl	ication	of:
------------	---------	-----

Raju, Jeyaseelan

Application No.:

10/626,173

Group No.:

1652

Filed:

July 24, 2003

Examiner:

Monshipouri, Maryam

For:

NOVEL CARK PROTEIN AND NUCLEIC ACID MOLECULES AND USES

THEREFOR

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

- 1. (x) Preliminary Statements
- 2. (x) Form PTO/SB/08B (6 pages)
- 3. [x] Copies of Listed Information Items Accompanying This Statement (54 references)

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"

Mailing Label No.

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

--Signaturé

Date: <u>January 11, 2005</u>

Sean Hunziker

(type or print name of person certifying)

*WARNING:Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI98-105P1RCP2DV1M

Preliminary statements

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in PTO/SB/08B (substitute for Form PTO-1449) accompany this information statement.

January 11, 2005

MILLENNIUM, PHARMACEUTICALS, INC.

By:

Mario Cloutier

Limited Recognition Under 37 C.F.R. §10.9(b)

40 Lansdowne Street

Cambridge, MA 02139

Telephone – (617) 577-3522

Facsimile – (617) 551-8820

Please type a plus sign (+) inside this box ->	+
	<u></u>

PTO/SB/08B (10-96) Approved for use through 10/31/99. OMB 0654-0031

MPI98-105P1RCP2DV1M

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of are required to respond to a collection of information unless it contains a valid OMB control number.

JAN 1 3 2005 Complete if Known Substitute for form 1449B/PTO INFORMATION DI **Application Number** 10/626,173 **Filing Date** July 23, 2004 STATEMENT BY APPLICANT **First Named Inventor** Raju, Jeyaseelan **Group Art Unit** 1652 (use as many sheets as necessary) **Examiner Name** Maryam Monshipouri Sheet of 6

Attorney Docket Number

**		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	C1	"Hypothetical Protein" 12 November 1999 (sequence) TrEMBL [online], Geneva, Switzerland, Swiss Institute of Bioinformatics [retrieved on January 7, 2005]. Retrieved from the Internet: URL:http://expasy.ch.sprot/ >. TrEMBL Accession No. Q9Y2V6.	
	C2	Jeffrey, P. D. et al., "Chain A, Cyclin A – Cyclin-Dependent Kinase 2 Complex." 14 July 1996 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL:http://www.ncbi.nlm.nih.gov/ >. GenBank Accession No. AF261233.	
	C3	Russo, A. A. et al., "Chain A, Phosphorylated Cyclin-Dependent Kinase-2 Bound to Cyclin A" 03 July 1996 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. 1JST_A.	
	C4	Sicheri, F. et al., "Chain A, Src Family Kinase Hck-Amp-PnP Complex" 20 February 1997 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ >. GenBank Accession No. 1AD5_A.	
	C5	Mohammadi, M. et al., "Chain A, Crystal Structure of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor 1" 08 February 1997 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/>. GenBank Accession No. 1FGK_A.	
	C6	Lisziewicz, J. et al., "Protein Kinase (EC 2.7.1.37), cAMP-Dependent, catalytic chain 1 — Yeast (Saccharomyces cerevisiae)" 21 July 2000 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/>. GenBank Accession No. OKBYC1.	
	C7	Xu, W. et al., "Crystal Structure of Human Tyrosine-Protein Kinase C-Src" 24 January 1997 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ , GenBank Accession No. 1FMK.	
	C8	Ebina, Y. et al., "Insulin Receptor (Tyrosine Kinase Domain) Mutant with Cys 981 Replaced By Ser and Tye 984 Replaced by the Phe (C981s, Y984f)" 04 December 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/>. GenBank Accession No. 1IRK.	
	C9	Tan, J. L. et al., "Protein-Tyrosine Kinase (EC 2.7.1.112) 1 – Slime Mole (Dictyostelium discoideum) (fragment)" 04 February 2000 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. A35670.	
	C10	NCI-CGAP, "ah70b01.s1 Soares_testis_NHT Homo Sapiens cDNA clone 1320937 3', mRNA sequence" 29 December 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: <u>URL: http://www.ncbi.nlm.nih.gov/</u> . GenBank Accession No. AA758546.	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here is English language Translation is attached.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known			
INIEC	RMATI		SCLOSURE	Application Number	10/626,173		
				Filing Date	June 23, 2004		
STATEMENT BY APPLICANT				First Named Inventor	Raju, Jeyaseelan		
				Group Art Unit	1652		
	(use as m	nany sheets a	s necessary)	Examiner Name	Maryam Monshipouri		
Sheet	2	of	6	Attorney Docket Number	MPI98-105P1RCP2DV1M		

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	C11	Hwang, D. M. et al., "M186 Fetal Heart, Lambda ZAP Express Homo Sapiens cDNA 5', mRNA sequence" 23 April 1997 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ >. GenBank Accession No. AA389675.	
	C12	NCI-cGAP, "op74a11.s1 Soares_NFL_T_GBC_S1 Homo sapiens cDNA clone IMAGE: 1582556 3', mRNA Sequence" 24 September 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/>. GenBank Accession No. AA938871.	
	C13	Shinn, P. et al., "F2401.13 [Arabidopsis thaliana]" 16 January 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ >. GenBank Accession No. AAB96858.	
	C14	Connell, M, "Caenorhabditis elegans cosmid C24A1, complete sequence" 03 December 2004 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ >. GenBank Accession No. AF024491.	
	C15	Miao, N. et al., "Rattus norvegicus pancreatic serine threonine kinase mRNA, complete cds." 13 Jun 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: <u>URL:</u> http://www.ncbi.nlm.nih.gov/ >. GenBank Accession No. AF068261.	
	C16	NCI-cGAP, "ow16c03.x1 Soares_parathyroid_tumor_NbHPA Homo Sapiens cDNA clone IMAGE: 1646980 3' similar to WP: C24A1.3 CE08335, mRNA Sequence" 30 June 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ >. GenBank Accession No. Al040439.	
	C17	NCI-cGAP, "qw21h08.x1 NCI_CGAP_Ut4 Homo sapiens cDNA clone IMAGE: 1991775 3', mRNA Sequence" 21 December 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. Al289394.	
	C18	NCI-cGAP, "qp98h10.x1 Soares_fetal_lung_NbHL19W Homo sapiens cDNA clone IMAGE: 1931107 3' similar to WP: C24A1.3 CE08335, mRNA Sequence" 28 December 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ >. GenBank Accession No. Al333762.	
	C19	NCI-cGAP, "tc09q12.x1 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE: 2063398 3' similar to WP: C24A1.3 CE08335, mRNA Sequence" 18 March 1999 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ >. GenBank Accession No. Al375137.	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here is English language Translation is attached.


Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	e for form 1449	В/РТО		Complete if Known			
INFC	RMAT	ION DIS	SCLOSURE	Application Number	10/626,173		
				Filing Date	June 23, 2004		
SIA	IEMEN	II BY A	PPLICANT	First Named Inventor	Raju, Jeyaseelan		
				Group Art Unit	1652		
	(use as i	many sheets a	s necessary)	Examiner Name	Maryam Monshipouri		
Sheet	3	of	6	Attorney Docket Number	MPI98-105P1RCP2DV1M		

	,	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	C20	NCI-cGAP, "te61c04.x1 Soares_NFL_T_GBC_S1 Homo sapiens cDNA clone IMAGE: 2091174 3', mRNA Sequence" 28 March 1999 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/>. GenBank Accession No. Al377988.	
	C21	Laidlaw, S. M. et al., "Fowlpox virus strain ank2, ank3, snap, cell, dnasell and pc1 genes." 14 July 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AJ006408.	·
	C22	Koetter, P. et al., "Putative protein [Arabidopsis thaliana]" 29 July 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ >. GenBank Accession No. CAA20048.	
	C23	Mahairas, G. G. et al., "HS_2061_A1_G12_T7 CIT Approved Human Genomic Sperm Library D Homo sapiens genomic clone Plate=2061 Col=23 Row=M, genomic survey sequence" 03 October 1998 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AQ242835.	
-	C24	Mahairas, G. G. et al., "HS_1026_B1_D03_MR.abi CIT Human Genomic Sperm Library C Homo sapiens genomic clone Plate=CT 805 Col=5 Row=H, genomic survey sequence" 17 October 1997 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ GenBank Accession No. B35049.	
	C25	Tanaka, T. et al., "CO3950 Human heart cDNA (YNakamura) Homo sapiens cDNA clone 3NHC2459, mRNA sequence" 30 July 1996 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/>. GenBank Accession No. C03950.	
	C26	Irie, K. et al., "Saccharomyces cerevisiae gene for Ssp31 Protein kinase, complete cds." 29 May 2002 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ >. GenBank Accession No. D10389.	
	C27	Toda, T. et al., "Yeast (S. cerevisiae) cAMP-Dependent Kinase subunit (TPK3) gene" 27 April 1993 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ >. GenBank Accession No. M17074.	
	C28	Tan, J. L. et al., "D.discoideum protein-tyrosine kinase-2 (DPYK2) mRNA, complete cds." 27 April 1993 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ >. GenBank Accession No. M33784.	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



¹Unique citation design number. ²Applicant is to place a check mark here is English language Translation is attached.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	e for form 1449	В/РТО		Complete if Known			
INFC	RMAT	ON DIS	CLOSURE	Application Number	10/626,173		
				Filing Date	June 23, 2004		
STATEMENT BY APPLICANT				First Named Inventor	Raju, Jeyaseelan		
		•		Group Art Unit	1652		
	(use as i	nany sheets as	necessary)	Examiner Name	Maryam Monshipouri		
Sheet	4	of	6	Attorney Docket Number	MPI98-105P1RCP2DV1M		

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	C29	Tan, J. L. et al., "D.discoideum protein-tyrosine kinase-1 (DPYK1) mRNA, complete cds." 27 April 1993 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. M33785.	
	C30	Feng, X. H. et al., "Glycine max protein kinase (PK6) mRNA, complete cds." 27 April 1993 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ GenBank Accession No. M67449.	
	C31	Toda, T. et al., "cAMP-Dependent Protein Kinase Type 3 (PKA 3)" 15 March 2004 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ >. SwissProt Accession No. P05986.	
	C32	Toda, T. et al., "cAMP-Dependent Protein Kinase Type 1 (PKA 1) (CDC25 suppressing protein kinase) (PK-25)" 25 October 2004 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . SwissProt Accession No. P06244.	
	C33	Friesen, H. et al., "Sporulation-specific protein 1." 01 August 1988 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . SwissProt Accession No. P08458.	
	C34	Lux, S. E. et al., "Ankyrin 1 (Erythrocyte ankyrin (Ankyrin R)" 01 April 1990 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ >. SwissProt Accession No. P16157.	
	C35	Nuckolls, G. H. et al., "Non-receptor tyrosine kinase spore lysis A (Tyrosine-protein kinase 1)" 01 November 1990 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ >. SwissProt Accession No. P18160.	_
	C36	Rhodes, N. et al., "Serine/threonine-protein kinase STE11" 01 November 1991 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ >. SwissProt Accession No. P23561.	
	C37	Fukami, Y., "Serine/threonine-protein kinase KIC1 (Kinase that interacts with CDC31) N-rich kinase 1)" 01 February 1995 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: <u>URL: http://www.ncbi.nlm.nih.gov/</u> >. SwissProt Accession No. P38692.	



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here is English language Translation is attached.

Approved for use through 10/31/99. OMB 0654-0031


Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO .				Complete if Known		
INFC	RMATI	ON DIS	SCLOSURE	Application Number	10/626,173	
STATEMENT BY APPLICANT				Filing Date	June 23, 2004	
				First Named Inventor	Raju, Jeyaseelan	
				Group Art Unit	1652	
	(use as n	nany sheets as	s necessary)	Examiner Name	Maryam Monshipouri	
Sheet	5	of	6	Attorney Docket Number	MPI98-105P1RCP2DV1M	

	_	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	C38	Costigan, C. et al., "Serine/threonine-protein kinase BCK1/SLK1/SSP31" 01 October 1993 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ SwissProt Accession No. Q01389.	
	C39	Otto, E. et al., "Ankyrin, Brain Variant 2 (Ankyrin B) (Ankyrin, Nonerythroid)" 01 November 1995 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ >. SwissProt Accession No. Q01485.	
•	C40	White R. A. et al., "Ankyrin 1 (Erythrocyte ankyrin)" 01 November 1995 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ >. SwissProt Accession No. Q02357.	
	C41	Hwang, D. M. et al., "F5349 Fetal Heart Homo Sapiens cDNA Clone F5349 5' end, mRNA sequence" 02 May 1996 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ >. GenBank Accession No. R57737.	
	C42	Chang, Y. N. et al., "orf IE94 {5' promoter region, domain A1 and A2 enhancer region} [simian cytomegalovirus SCMV, Colburn, Genomic, 751 nt]" 08 May 1993 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. S51380.	
	C43	Adler, K., "Dictyostelium discoideum AX2 protein tyrosine kinase mRNA, partial cds." 24 July 1996 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ >. GenBank Accession No. U01064.	
	C44	Otsuka, A. J. et al., "Caenorhabditis elegans ankyrin-related protein UNC-44 (unc-44) gene, partial cds." 27 January 1996 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. U21734.	
	C45	Otsuka, A. J. et al., "Caenorhabditis elegans A013 ankyrin, A066 ankyrin and A049 Ankyrin (unc-44) gene, three alternatively spliced forms, complete cds." 04 February 1997 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ >. GenBank Accession No. U39847.	
	C46	Gattung, S., "Caenorhabditis elegans cosmid B0350, complete sequence" 25 October 2004 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ GenBank Accession No. U50071.	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.





¹Unique citation design number. ²Applicant is to place a check mark here is English language Translation is attached.

PTO/SB/08B (10-96) Approved for use through 10/31/99. OMB 0654-0031


Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known		
				Application Number	10/626,173	
				Filing Date	June 23, 2004	
				First Named Inventor	Raju, Jeyaseelan	
				Group Art Unit	1652	
(use as many sheets as necessary)				Examiner Name	Maryam Monshipouri	
Sheet	6	of	6	Attorney Docket Number	MPI98-105P1RCP2DV1M	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	-
Examiner Initials*	Cite No.1	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	C47	Lux, S. E. et al., "Human mRNA for ankyrin (variant 2.1)" 04 April 1995 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. X16609.	
	C48	Otto, E. et al., "Homo Sapiens mRNA for ankyrin, Brank-2 protein" 10 May 1999 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ >. GenBank Accession No. X56958.	
	C49	Katoh, M. et al., "H. sapiens MST mRNA for serine/threonine kinase" 30 august 1995 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ >. GenBank Accession No. Z48615.	
	C50	Bevan, M. et al., "Arabidopsis thaliana DNA chromosome 4, ESSA I FCA contig fragment No. 2" 29 June 1999 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: <u>URL: http://www.ncbi.nlm.nih.gov/</u> >. GenBank Accession No. Z97337.	
	C51	Bowman, S. et al., "Plasmodium Falciparum MAL3P6, complete sequence" 29 January 2003 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ >. GenBank Accession No. Z98551.	
	C52	Cosentino, M. T. et al., "Rattus norvegicus ankyrin mRNA, membrane binding domain, partial cds." 17 February 1997 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ >. GenBank Accession No. U65916.	
	C53	Wu, L. C. et al., "Human BRCA1-associated RING domain protein (BARD1) mRNA, complete cds." 10 December 1996 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. U76638.	
	C54	Lee, K.S. et al., "S. cerevisiae BCK1 gene for protein kinase" 13 March 1992 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ >. GenBank Accession No. X60227.	

Examiner		Date	
Signature	•	Considered	



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here is English language Translation is attached.